Biopharmaceuticals
-
Probiogen Signs Therapeutic Protein Process Development Contract with Virdante
ProBioGen, a technology and service provider for the development and production of biopharmaceutical drug substances, has announced the signing of a contract with Virdante Biopharmaceuticals, a US-based biopharmaceutical development company. The f…
Biopharmaceuticals | 28 May 2010
-
Biopharmaceuticals: Shifting Landscapes
The industry is undergoing changes as Big Pharma buys out smaller biotech and pharmaceutical companies.
Biopharmaceuticals | 01 March 2010
-
Intas Biopharmaceuticals Wins Award for Quality Excellence in India
Intas Biopharmaceuticals has received Gold Award for Quality Excellence in the category of Formulations Unit. The award was conferred by Indian Drug Manufacturer’s Association (IDMA). The awards were presented by B S Jharwar, chairman, National…
Biopharmaceuticals | 05 February 2010
-
Animal-Free Solutions for Biopharmaceuticals
Yeast expression systems and proprietary protein engineering technologies provide flexibility in the production of therapeutic proteins with extended circulatory half-life.
Biopharmaceuticals | 01 November 2009
-
Intas Biopharma to Market Drug for Multiple Myeloma
India-based oncology drug marketing company, Intas Biopharmaceuticals, has launched Bortezomib injection, under the brand name Borviz, in the Indian market. The injection offers treatment for Multiple Myeloma, the second-most common cancer of plasma …
Biopharmaceuticals | 22 May 2009
-
DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6 technology platform
DSM and Crucell has announced fermentation yields of more than 10 grams per liter for monoclonal antibodies, a major breakthrough in the development of their PER.C6 technology platform, meeting their key objective set early last year. This resul…
Biopharmaceuticals | 16 February 2007
-
Lonza and Bio*One Capital to Build Biopharmaceuticals Facility in Singapore
Swiss-based Lonza Group has signed an agreement with Singapore’s Bio*One Capital to construct a large-scale mammalian cell culture plant in Singapore for the manufacture of commercial bio-pharmaceuticals. Due to become operational at the end of…
Biopharmaceuticals | 01 April 2006
